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Antisense Ablation of Type I Metabotropic Glutamate Receptor
mGluR1 Inhibits Spinal Nociceptive Transmission
Marie R. Young,1 Gordon Blackburn-Munro,1 Tracey Dickinson,1 Melanie J. Johnson,2 Heather Anderson,1
Immaculate Nakalembe,1 and Susan M. Fleetwood-Walker1
1Department of Preclinical Veterinary Sciences, Royal (Dick) School of Veterinary Studies, University of Edinburgh,
Summerhall, Edinburgh EH9 1QH, United Kingdom, and 2Medical Research Council Brain Metabolism Unit, Edinburgh
EH8 9JZ, United Kingdom
Electrophysiological and behavioral studies point to a role of
group I metabotropic glutamate receptors (mGluR1 and
mGluR5) in mediating spinal nociceptive responses in rats.
However, antagonists with a high degree of specificity for each
of these sites are not yet available. We, therefore, examined the
effects of antisense deletion of spinal mGluR1 expression in
assays of behavioral analgesia and of electrophysiological re-
sponses of dorsal horn neurons. Rats treated with an mGluR1
antisense oligonucleotide reagent, delivered continuously to
the intrathecal space of the lumbar spinal cord, developed
marked analgesia as measured by an increase in the latency to
tail-flick (55°C) over a period of 4–7 d. This correlated with a
selective reduction in mGluR1, but not mGluR5, immunoreac-
tivity in the superficial dorsal horn compared with untreated
control rats, in parallel with a significant reduction in the pro-
portion of neurons activated by the mGluR group I agonist
3,5-dihydroxyphenylglycine (DHPG), whereas the proportion of
cells excited by the mGluR5 agonist, trans-azetidine-2,4-
dicarboxylic acid (t-ADA) remained unaffected. In contrast, rats
treated with mGluR1 sense or mismatch probes showed none
of these changes compared with untreated, control rats. Fur-
thermore, multireceptive dorsal horn neurons in mGluR1
antisense-treated rats were strongly excited by innocuous stim-
uli to their peripheral receptive fields, but showed severe re-
ductions in their sustained excitatory responses to the selective
C-fiber activator mustard oil and in responses to DHPG.
Key words: metabotropic glutamate receptors; mGluR1;
mGluR5; dorsal horn; nociception; antisense oligodeoxynucle-
otide probe
There is a large body of evidence supporting a role for the
excitatory amino acid glutamate in mediating sensory information
at the first central synapses in the dorsal horn of the spinal cord.
Glutamate receptors in mammalian brain are classified into two
functional groups: ionotropic and metabotropic receptors
(mGluRs), (Nakanishi, 1992). The metabotropic group of gluta-
mate receptors, comprising eight receptors, is subdivided into
three groups, according to their amino acid homology, pharma-
cological, and signal transduction profiles: group I (mGluRs1/5),
group II (mGluRs2/3), and group III (mGluRs4/6/7/8) (Masu et al.,
1991; Abe et al., 1992; Nakanishi, 1992; Pin and Duvoisin, 1995).
The mGluRs, which couple via G-proteins to several signal trans-
duction pathways, regulate neuronal excitability in the CNS by
modulating a variety of ion channels (for review, see Saugstad et
al., 1995). Many of the mGluRs have been shown to be present in
the spinal cord (Shigemoto et al., 1992, 1993; Ohishi et al., 1993,
1995; Vidnya´nszky et al., 1994; Anneser et al., 1995; Romano et
al., 1995; Boxall et al., 1996; Petralia et al., 1996; Valerio et al.,
1996) where they appear to play a role in mediating nociceptive
inputs in the dorsal horn of the spinal cord (Neugebauer et al.,
1994; Young et al., 1994, 1995, 1997), as well as in the thalamus
(Eaton et al., 1993). In particular (but not exclusively) group I
mGluR1/5 receptors have been implicated in nociceptive re-
sponses (Young et al., 1994, 1995, 1997; Fisher and Coderre,
1996a,b; Fundytus et al., 1998), and their actions may be medi-
ated, at least in part, by protein kinase C (Young et al., 1995).
This role appears to be more prominent after sustained noxious
stimuli, such as intraplantar formalin and carrageenan-induced
inflammation, where mGluR antagonists prolong the latency of
behavioral nociceptive responses (Fisher and Coderre, 1996b;
Young et al., 1997) or inhibit the sustained responses of dorsal
horn neurons to mustard oil (Young et al., 1997). mGluR1/5
agonists can increase the excitability of dorsal horn neurons
(Morisset and Nagy, 1996) and facilitate responses to NMDA and
AMPA receptor activation (both of which are likely to participate
in processing sustained nociceptive inputs) (Bleakman et al.,
1992; Cerne and Randic, 1992; Bond and Lodge, 1995; Jones and
Headley, 1995). Similarly, administration of mGluR1/5 agonists
appears to interact with an NMDA (and/or AMPA) receptor-
dependent mechanism to increase nociceptive behavioral re-
sponses to intradermal formalin injection and to noxious sensory
stimuli (Coderre and Melzack, 1992; Meller et al., 1993, 1996;
Fisher and Coderre, 1996b). In both electrophysiological and
behavioral studies, agonists and antagonists with selectivity for
mGluR1/5 (as well as neutralizing antibodies) are effective
(Young et al., 1995, 1997; Fisher and Coderre 1996a,b; Fundytus
et al., 1998), and some of the agents used show partial selectivity
for mGluR1 over mGluR5 (Hayashi et al., 1994; Sharp et al., 1994;
Brabet et al., 1995; Kingston et al., 1995). Nevertheless, because
the available pharmacological reagents are not wholly specific, we
have taken the alternative strategy of antisense deletion of spinal
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mGluR1 expression to gain an unequivocal assessment of its role
in nociceptive processing.
MATERIALS AND METHODS
Animals and evaluation of analgesia. Adult male Wistar rats (weight
280–450 gm, Charles River, Kent, UK) were used. Measurements of
tail-flick latency (using a modified Ugo Basile tail-flick unit made in-
house) of each rat (30–55°C to the base of the tail) were made for 3 d
before, and recommencing 4 d after implantation of an indwelling intra-
thecal silicone cannula connected to an osmotic minipump for the con-
tinuous, quantitative administration of sense, missense, and antisense
mGluR1 oligonucleotides (see below).
Oligonucleotide probes and implantation of osmotic minipump. The
21-base antisense oligodeoxynucleotides endcapped with phosphorothio-
ate linkages (at the positions marked by *) were designed according to
the primary sequence of the rat mGluR1 cDNA (Houamed et al., 1991;
Masu et al., 1991). The sequence of the mGluR1 antisense probe was:
59-G*C*CGGACCATTGTGGCGAAG*A*-39, targeted around the
translation initiation site (nucleotides 211 to 110) and will clearly not
differentiate between splice variants in the carboxyl tail region. The
complementary mGluR1 sense probe used: 59-T*C*TTCGCCACA-
ATGGTCCGG*C*-39, corresponds to the reverse order of nucleotides of
the above. The mismatch probe was: 59-T*C*CGGATCATTGG-
GGCGACG*A*-39. None of the oligonucleotide probes shows internal
complementarity nor resembles any other known sequences according to
the GenBank Database. Custom synthesis, HPLC-purification, and gel
filtration were performed by Oswel DNA Service (Southampton, UK),
and probes were dissolved and aliquoted in sterile 0.9% saline, pH 7.4, to
give 0.25 mg/ml final concentration for infusion, before being stored at
220°C until use.
For continuous infusion into the intrathecal lumbar spinal cord region,
each rat was implanted with a minipump with cannula attachment, which
was assembled the day before surgery. It consisted of an osmotic
minipump [Alza Minipump, model 2001 (Palo Alto, CA); nominal infu-
sion rate, 1 ml /hr) attached to two lengths of sterile cannulae: first, to the
pump, a length of ;1 cm of vinyl cannula (internal diameter 0.76 mm,
outer diameter 0.99 mm) and to this was fitted second, a length of ;6 cm
of silicone cannula (internal diameter 0.64 mm, external diameter 1.20
mm) (Degania Silicone). The pump and cannulae were filled with one of
the above solutions (or saline control) under sterile conditions, and then
the cannulae were joined to the pump, avoiding air bubble formation,
before being placed in sterile saline at 37°C overnight.
Surgery was performed under sterile conditions, with Sagatal (Rhone
Merieux, Harlow, Essex, UK; 0.06 ml/100 gm, i.p.) anesthesia, followed
by a maintenance level of halothane (Zeneca, Cheshire, UK). The
minipump was placed intramuscularly at an interscapular site, and the
caudally directed cannula was threaded through muscle close to the
exposed region of the spinal column. A small area of muscle and verte-
bral bone was cleared from two dorsal thoracic segments (T10–T12), and
the tip of the cannula was placed through a small incision, under the
dura, and eased down the dorsal spinal cord by a premeasured distance,
to within the region of the lumbar segments L3–L6. After resection of the
wound, the rat was then kept for up to 7 d, and its behavior was
monitored (see above) before it was either (1) used for an electrophysi-
ological recording experiment or (2) perfused and tissue taken for
immunohistochemistry. A further group of rats were assessed behavior-
ally for 1 week subsequent to a 7 d infusion of antisense, to assess
recovery. The position of the tip of the cannula with respect to the level
of spinal segment was ascertained at the end of each experiment, and
only data from animals with correct cannula placement (L3–L6) were
used in analysis. No animal showing abnormal gait or paralysis during the
7 d period was included in the study.
Electrophysiolog ical studies. To assess the physiological effects of the
loss of receptor expression after mGluR1 antisense treatment, neuronal
responsiveness to ionophoretically applied mGluR agonists was investi-
gated. Experiments were performed on 60 rats. Under initial halothane
anesthesia, the jugular vein and trachea were cannulated. Intravenous
a-chloralose (60 mg/kg) and urethane (1.2 mg/kg) with supplementary
doses of a-chloralose (10 mg/ml) were given throughout the experiment
as required. Core body temperature was maintained at 37–38°C by means
of a thermostatically controlled heated blanket. Animals inspired
oxygen-enriched air. The animal was placed in a stereotaxic frame, and
the thoracolumbar spinal column was supported using three pairs of
swan-necked clamps. A laminectomy was performed at L2–L5, and agar
(2% in saline at 37°C) was injected under the most rostral vertebra and
over the exposed cord to increase mechanical stability. Above the re-
cording region, a section of the now solidified agar was removed, the dura
was removed, and liquid paraffin (37°C) was poured over the exposed
cord. Extracellular recordings were made from single neurons in laminae
III–V through the center barrel of a seven-barelled glass microelectrode
filled with 4 M NaCl (pH 4.0–4.5, tip diameter 4–5 mm, DC resistance
5–8 MV). The bandwidth of the recording amplifier was 1 Hz to 7 kHz.
The following drugs were ionophoresed from the side barrels of the
electrode: group I mGluR agonist: 3,5-dihydroxyphenylglycine (DHPG),
10 mM aqueous, pH 4.5; mGluR5 agonist: trans-azetidine-2,4-dicarboxylic
acid (t-ADA), 10 mM aqueous, pH 8.0–8.5; and the AMPA receptor
agonist: AMPA, 10 mM aqueous, pH 8.0–8.5. All compounds were
obtained from Tocris Cookson, Bristol, UK. Retention currents of 10 nA
were used to minimize drug leakage between tests. A remaining barrel
contained 1 M NaCl, pH 4.0–4.5, for automatic current balancing, using
a Neurophore BH2 ionophoresis system (Medical Systems, Great Neck,
NY) and for current controls. The resistance of all side barrels was 20–30
MV.
Recordings were made from any multireceptive neuron encountered at
a depth from the dorsal surface corresponding to laminae I–IV, as shown
in previous studies using electrophoretic deposition of dye (Fleetwood-
Walker et al., 1988, 1993). The cutaneous receptive fields of neurons
were identified by innocuous brush stimuli and were all on the distal
hindlimb. The use of a mechanized rotating fine brush to stimulate hair
follicle (Ab) afferents has been described previously (Fleetwood-Walker
et al., 1985) and was qualitatively innocuous to human skin. Further
characterization was performed using noxious radiant heat (30–48°C,
rise time 5 sec, plateau temperature for 10 sec) and noxious pinch.
Approximately 90% of all the cells tested in normal animals also showed
sustained responses to mustard oil. The responses of cells to ionophore-
sed agonists were then explored with drug ejection currents being in-
creased in a stepwise manner, every minute in steps of 10 nA from 5 to
45 nA. The response of neurons to the chemical algogen mustard oil
(allyl isothiocyanate; Sigma, Poole, UK; 7.5% in paraffin oil) was ob-
served after being repeatedly applied to the receptive field area (nor-
mally ;2 cm 2) every 5 min until sustained activation occurred.
Statistical analysis of the proportion of cells activated by agonists in
the different groups of rats (normal, antisense reagent-treated, or sense
reagent-treated rats) was performed by Mann–Whitney U test.
Immunohistochemistry. To directly monitor the loss of receptor protein
expression after 5 d of intrathecal treatment with the mGluR1 antisense
oligonucleotide probe, immunohistochemical analysis of the lumbar spi-
nal cord was performed. Animals taken for immunohistochemistry were
deeply anesthetized with Sagatal (0.12 ml/100 gm, i.p.) and perfused
transcardially with 0.1 M PBS (containing 3 mM sodium nitrite and 1000
U heparin, pH 7.4) before being perfused with 4% paraformaldehyde/0.1
M PBS. A laminectomy was then performed, and the spinal cord was
removed, together with the brain, which were then post-fixed in the same
solution for a further 4–5 hr, before being incubated in 25% buffered
sucrose overnight (4°C) and then stored in cryoprotectant (30% ethylene
glycol and 20% glycerol, in 0.05 M PBS, pH 5.5) at 270°C. Transverse
microtome sections (52 mm) were then cut from the frozen tissue,
through lumbar segments L3–L6, and suitable sections of brain tissue
were used as positive controls for the antibodies used. Tissue sections
were stored in cryoprotectant at 220°C, until use. Sections were removed
from the cryoprotectant as required, for processing for either mGluR1 or
mGluR5 immunoreactivity. Unless otherwise stated, all solutions were
made up in 0.1 M PBS, and all incubations were performed at room
temperature with gentle agitation. In all steps involving antibodies, the
tissue sections were washed twice, for 10 min each, with PBS between
succeeding steps. Sections were incubated in 1% hydrogen peroxide (30
min; Sigma) to remove any endogenous peroxidase activity, followed by
incubation in normal goat serum (1 hr) to block nonspecific binding.
They were then incubated with polyclonal antipeptide antibodies raised
to rat mGluR1 (1180–1199) (0.25 mg/ml, 48 hr, 4°C; Chemicon, Temecula,
CA) or rat mGluR5 (1152–1171) (1 mg/ml, 48 hr, 4°C; Upstate Biotechnol-
ogy, Lake Placid, NY) followed by biotinylated goat anti-rabbit IgG
antibody (1: 200 in PBS, 1 hr; Vector Laboratories, Peterborough, UK).
Sections were then incubated for 90 min with an avidin–biotin complex
solution (Vectastain Elite ABC kit, Vector Laboratories). A further wash
with PBS was followed by exposure of sections to a solution of 3,39
diaminobenzidine tetrachloride (DAB; 0.2 mg/ml; Sigma) in the pres-
ence of 3% hydrogen peroxide (1 mg/ml) to enable visualization of the
receptor protein precipitate. After a final wash in PBS, the sections were
mounted onto poly-L-lysine-coated microscope slides, allowed to air dry
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before dehydration through ascending concentrations of alcohol, and
then cleared in xylene (Sigma) and mounted in DePex mountant (BDH).
Further immunohistochemical controls consisted of replacing the pri-
mary antibodies with nonimmune goat serum, or for preabsorbtion
controls, see below. To overcome any potential problems caused by
variable development of the DAB reaction, batches of control, sense,
mismatch, and antisense-treated spinal sections were processed simulta-
neously, meaning that direct comparisons between them could be con-
fidently made.
As a preabsorbtion control for specificity of the mGluR1 antibody,
aliquots were incubated with membranes from COS 7 cells overexpress-
ing the rat mGluR1a receptor from a construct in pcDNA 1 (a gift from
S. Nakanishi, Kyoto University, Japan) or with membranes from control
COS 7 cells. Transfections were performed using DEAE dextran, and
cells were harvested 72 hr later (Lutz et al., 1993). Cells were homoge-
nized, and the crude particulate fraction was washed twice in ice-cold 20
mM HEPES-NaOH, pH 7.2, with phosphatase and peptidase inhibitors.
Antibody aliquots were incubated with membranes (16 hr rolling at 4°C)
before use (at twice the usual concentration). Preincubation with normal
COS 7 cell membranes had no detectable effect, showing staining in
normal dorsal horn apparently identical to that with untreated antibody,
whereas the mGluR1-expressing membranes caused virtually complete
loss of immunostaining (see Fig. 3E).
Relative quantification of immunoreactivity was achieved using an
Improvision 1.49 image analysis package at 4003. An 80 3 30 mm region
of interest (ROI) cursor was aligned consecutively, centered on laminae
I, IIouter , IIinner , and III and, in ventral horn, 40 mm diameter ROIs were
centered over individual motoneurons. Arbitrary gray scale units
(throughout the range 1–200) were assigned to make optimal use of the
range for the given sample set. Each section was corrected for the (low)
nonspecific background levels recorded from white matter. Individual
measurements were performed on 15 or 16 separate sections for each
experimental condition.
Gel electrophoresis and immunoblotting. L3–L6 spinal cord samples,
which had been frozen at 270°C were thawed into standard Laemmli
lysis buffer and denatured at 100°C for 5 min. Proteins were separated by
electrophoresis on precast, 20% polyacrylamide minigels (Phast System;
Pharmacia, Piscataway, NJ) and transferred to immobilon (Johnson et
al., 1993). After blocking with Marvel overnight at 4°C, blots were
incubated with the primary mGluR1 (1:200) or mGluR5 (1:300) antibod-
ies. HRP-conjugated donkey anti-rabbit IgG (1:5000) and the Enhanced
Chemiluminescence kit (Amersham, Arlington Heights, IL) were used to
visualize immunoreactive bands.
RESULTS
The position of the implanted intrathecal cannula was verified
4–7 d after surgery to ensure that only those animals with correct
L3–L6 placements were taken for subsequent electrophysiological
recording experiments or immunohistochemistry. For the ani-
mals included in this study, cannulae were found to lie on the
dorsal surface of the spinal cord.
Measurement of behavioral nociceptive responses
Tail-flick latency was measured for 2–3 d before, and also after,
surgical implantation of an indwelling intrathecal cannula to the
lumbar spinal cord, allowing an intermediate 3 d gap for recovery
from surgery.
After continuous infusion of the mGluR1 antisense oligonucle-
otide probe, there was a marked increase in tail-flick latency
reaching a peak at 4–7 d after surgery, which was statistically
significant compared with presurgery levels ( p , 0.05; Mann–
Whitney U test, n 5 9), saline-infused controls, mismatch-treated,
or the sense-treated rats (Fig. 1). In the subsequent 7 d, the
tail-flick latency recovered steadily to values approaching presur-
gery controls, with 36 6 5%, 78 6 12%, and 88 6 4% recovery at
days 10, 12, and 14 after surgery, respectively (n 5 4). The
mGluR1 antisense oligonucleotide-treated animals that were sub-
sequently taken within 7 d after minipump and cannula implan-
tation surgery, for either electrophysiological studies or immuno-
histochemical investigation, all displayed delayed behavioral
nociceptive responses.
Electrophysiological recording experiments
Responses to mGlu receptor agonists
In all experimental rats that were taken for electrophysiological
recording experiments, ionophoretic application of the mGluR
agonists DHPG or t-ADA was performed at between 5 and 45
nA, at which every minute the ionophoretic current was increased
by 10 nA increments until activation was observed, or if none was
observed by 45 nA after 2 min, then the drug application was
terminated. Activation of cells occurred within the 5 sec to 2 min
after the drug had initially been applied. Most cells were activated
within 50 sec of either of the drugs being increased to 25 nA.
In normal animals, the mGluR1/5 agonist DHPG, administered
in this regimen, caused overt activation of a majority of multire-
ceptive cells (56%), whereas the mGluR5 agonist t-ADA acti-
vated a significantly smaller proportion (23%). Table 1 illustrates
Figure 1. Effects of mGluR1 sense, mismatch, and antisense oligonucle-
otide administration on behavioral nociceptive responses (tail-flick la-
tency, in seconds, to noxious heat applied to the base of the tail).
Statistically significant increases to tail-flick latency are indicated by *
( p , 0.05; Mann–Whitney U test). Attenuation of behavioral nociceptive
responses was observed 4–7 d after continuous infusion of the mGluR1
antisense oligonucleotide reagent (F) in saline to the lumbar spinal cord
segments L3–L6, compared with saline-infused controls (E), sense (M),
or mismatch () oligonucleotide-treated rats with similarly placed intra-
thecal cannulae. Values are means 6 SEM (n 5 6–14). Where error bars
are not apparent, they fall within the dimensions of the symbol.
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this, together with corresponding data from antisense, sense, and
mismatch-infused animals. A marked and significant reduction in
the proportion of cells responding to DHPG was seen after
antisense, but not the control reagents. The possibility that non-
identical samples of neurons may have been recorded in control
and antisense-treated animals cannot be excluded, but the pro-
portion of cells responding to t-ADA was not altered by any
treatment. Furthermore, ionophoretic application of AMPA
(10–40 nA) consistently caused very marked and rapid activation
of all cells tested, irrespective of whether they had been treated
with oligonucleotides or were untreated controls (data not
shown).
Sensory responses
Although dorsal horn neurons displayed vigorous responses to
motor-driven innocuous brush, which was unaffected by mGluR1
sense, mismatch, or antisense oligonucleotide treatments (Table
2), the same neurons showed a greatly reduced ability to respond
to noxious chemical stimulation after the mGluR1 antisense oli-
gonucleotide treatment.
In normal, untreated animals, neuronal activity increased
shortly after application of mustard oil to the peripheral receptive
field, quickly reaching a peak (at 20–40 sec) and then slowly
declining over the next 5 min. This acute chemical nociceptive
response (calculated as the mean value over 10 sec, 20–40 sec
after initial application) was not significantly altered in sense or
mismatch oligonucleotide-treated animals compared with un-
treated controls, whereas responses from antisense
oligonucleotide-treated animals were markedly reduced ( p ,
0.05; Mann–Whitney U test; Table 2). These observations concur
with the changes in acute thermal nociceptive responses (tail-
flick) seen in the behavioral experiments. Mechanical nociceptive
responses were not investigated quantitatively in the present
study.
In normal, untreated animals (n 5 8), eight of nine cells showed
a sustained and incremental excitatory response to repeated,
topical application of mustard oil to their peripheral receptive
field (up to three applications, every 5 min). The average increase
in ongoing activity of these neurons after topical mustard oil
application was from 0.3 6 0.1 Hz before mustard oil to 10.1 6 2.6
Hz of sustained activity, measured as the mean over 10 sec taken
15–18 min after initial application (Fig. 2A). Similarly, in the
mGluR1 sense oligonucleotide-treated control animals (n 5 5),
seven of eight multireceptive cells showed a sustained excitatory
response, after three topical mustard oil applications [from 0.2 6
1.0 Hz before mustard oil application to 7.4 6 1.8 Hz sustained
activity measured 15–18 min after initial application (Fig. 2B)].
Six cells recorded from mismatch-treated animals (n 5 6) (Fig.
2C) also showed marked ongoing activation as in normals (0.1 6
0.8 Hz before repeated mustard oil application and 7.3 6 1.6 Hz
afterward). In contrast, in rats treated with the mGluR1 antisense
oligonucleotide, which displayed greatly attenuated behavioral
nociceptive responses (n 5 6), six of six dorsal horn multirecep-
tive cells showed no significant sustained response to repeated
topical application of mustard oil to their peripheral receptive
field (even with up to five applications); the average increase in
ongoing activity being from only 0.1 6 0.1 Hz before mustard oil,
to only 0.5 6 1.8 Hz (Fig. 2D). The sustained mustard oil-induced
firing in antisense oligonucleotide-treated animals was signifi-
cantly less than that in control or sense-treated animals ( p , 0.05
by Mann–Whitney U test). All of the cells from which we re-
corded full sensory responses in normals, sense, and mismatch
animals also showed clear responses to DHPG. In the six cells
from antisense animals, from which we were able to gain ade-
quate records of both brush and some residual mustard oil re-
sponse, we found none that responded to DHPG.
Immunohistochemistry and immunoblotting for
mGluR1 and mGluR5
The specificity of antibody labeling was verified by analyzing the
distribution of mGluR1 and mGluR5 immunoreactivity in the
CNS. In the cerebellar cortex, the molecular and Purkinje layers
were strongly immunoreactive for mGluR1, whereas the granular
layer was less intensely labeled. The mGluR5 immunoreactivity in
the hippocampus was highest in the molecular layer, whereas
there were many unlabeled cell bodies in the CA1 and CA3 fields.
These observations are entirely consistent with previously pub-
lished observations (Shigemoto et al., 1992, 1993; Romano et al.,
1995).
In lumbar spinal cord of control untreated animals, neural
elements strongly labeled for mGluR1 were distributed in lami-
nae I and II of the dorsal horn, to a lesser extent in deeper dorsal
horn, and also in the ventral horn around motoneurons (Fig.
3A,F). This pattern of immunoreactivity was unchanged in ani-
mals treated with the mGluR1 sense or mismatch oligonucleotide
probe (Fig. 3B,C). In contrast, animals treated with the antisense
Table 1. Effect of mGluR1 antisense treatment on neuronal responses
to DHPG and t-ADA
Treatment
Percentage of cells excited by agonist
DHPG t-ADA
Control (n 5 13) 56 (25/45) 23 (6/26)*
Sense (n 5 7) 53 (16/30) 21 (8/38)
Mismatch (n 5 6) 55 (12/22) 27 (6/22)
Antisense (n 5 7) 20 (13/64)** 25 (12/49)
Drugs were ionophoresed at 5–45 nA for 5 sec to 2 min. The numbers of cells
responding, of those tested, are shown in parentheses, and the numbers of animals
in each case are shown after the respective treatments. (*p , 0.05; **p , 0.01
compared to control response to DHPG in control, sense, and mismatch; x2 test).
Table 2. Effects of sense, mismatch, and antisense mGluR1















(n 5 8) (n 5 7) (n 5 6) (n 5 6)
Innocuous brush 17.2 6 2.3 22.1 6 5.7 14.5 6 2.4 20.4 6 5.6
Acute chemical nociception 30.7 6 7.2 22.7 6 7.7 20.9 6 3.9 1.4 6 0.5*
Sustained activity caused by
repeated nociceptive
stimuli 10.1 6 2.6 7.4 6 1.8 7.3 6 1.6 0.5 6 1.8*
The sensory responses monitored were the acute neuronal responses to innocuous
brush (mean taken over 10 sec) and the chemical algogen mustard oil applied to the
peripheral receptive field (mean taken over 10 sec, 20–40 sec after initial applica-
tion), as well as the sustained sensitized activity caused by repeated application of
mustard oil (mean taken over 10 sec, 15–18 min after the first three applications).
Basal firing rates of neurons were all within the range 0–1.0 Hz and were no different
between treatments. Values are means 6 SEM with numbers of neurons in paren-
theses. *Indicates significantly different from normal, sense, or mismatch reagent
controls; p , 0.05, Mann–Whitney U test.
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Figure 2. Ongoing neuronal activity records showing typical excitatory firing responses of dorsal horn neurons to innocuous brush stimuli (M), to
ionophoresis of DHPG (u), and to noxious mustard oil stimulation (f). A shows untreated control, B shows mGluR1 sense oligonucleotide-treated, C
shows mGluR1 mismatch-treated, and D shows mGluR1 antisense-treated animals. All animals were tested for tail-flick responses before electrophys-
iological recording and were found to conform to the pattern displayed in Figure 1.
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Figure 3. Effects of mGluR1 sense, mismatch, and antisense infusion on mGluR1 and mGluR5 immunoreactivity in lumbar spinal cord. A–D show
typical representations of mGluR1 immunoreactivity in dorsal horn in control (saline), sense, mismatch, and antisense reagent-treated animals. E shows
the virtual lack of immunoreactivity in control dorsal horn when the mGluR1 antibody was preabsorbed with membranes from mGluR1-overexpressing
cells. F and G show mGluR1 immunoreactivity in ventral horn in control and mGluR1 antisense-treated animals. These results are typical of at least five
animals in each case. Scale bars, 1.0 mm. H shows immunoblots using mGluR1 and mGluR5 antibodies after gel electrophoresis of lysates from spinal
cord segments L3–L6 of (1) control, (2) antisense, (3) sense, and (4) mismatch-treated animals. The running positions of the molecular weight markers
are shown in kilodaltons. Results are typical of three separate experiments.
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oligonucleotide for mGluR1, which had displayed attenuated
behavioral nociceptive responses, showed a marked decrease in
the intensity and distribution in immunoreactive labeling for
mGluR1 in the superficial layers of the dorsal horn (Fig. 3D).
These losses were routinely observed throughout the extent of
L3–L6, after cannula placement at any point within this range,
thus giving a minimal estimate of the extent of reagent diffusion.
Under the present experimental conditions, the immunoreactiv-
ity for mGluR1 that was associated with motoneurons in the
ventral horn did not appear to be altered in the mGluR1 antisense
oligonucleotide-treated rats (Fig. 3G). Antibody specificity was
demonstrated by preabsorbtion with membranes from COS 7
cells overexpressing recombinant rat mGluR1a (Fig. 3E). Table 3
shows quantification of the mGluR1 immunostaining as gray scale
intensity measured across different laminae of the superficial
dorsal horn, demonstrating significant reductions in inner (and to
a slightly lesser extent, outer) lamina II of antisense-treated
animals compared with the other conditions. This loss was con-
firmed independently in Western blots from polyacrylamide gel
electrophoresis of spinal cord lysates (Fig. 3H). These showed a
single mGluR1-immunoreactive band at ;160–175 kDa that was
clearly depleted in samples from antisense-treated animals com-
pared with others. In contrast, mGluR5 immunoreactivity (which
was also concentrated in the superficial dorsal horn) showed no
differences in the pattern of staining in animals treated with
sense, mismatch, or antisense mGluR1 reagents compared with
normals (Table 3). In addition, Western blots showed the main
band of mGluR5 immunoreactivity (at ;160–180 kDa) was un-
altered by mGluR1 antisense treatment (Fig. 3H).
DISCUSSION
Various lines of evidence point to a role of mGluRs in spinal
somatosensory processing and reflex responses. It appears that
mGluRs of group I, II, and III may all have some role to play. The
group I/II mGluR agonist, 1S,3R-ACPD (1S,3R-1-amino-1,3-
cyclopentane dicarboxylic acid) causes postsynaptic increases in
the excitability of dorsal horn neurons (Morisset and Nagy, 1996),
and it has been suggested that not only group I, but also group II,
mGluRs may contribute to this effect (Bond and Lodge, 1995). In
fact, synergistic effects of group I and group II receptor agonists
on second messenger production have been described (Schoepp
et al., 1996). Group III and group II receptors at presynaptic sites
act to inhibit synaptic inputs to ventral horn neurons (Jane et al.,
1996) and may also modulate inputs to dorsal horn neurons.
Correspondingly, mGluR7 (group III) sites have been identified
in primary afferent terminals (Ohishi et al., 1995).
Nevertheless, the present data, together with the other avail-
able information from electrophysiological and behavioral stud-
ies, suggest strongly that group I mGluRs play a crucial role in
physiological nociceptive inputs (Neugebauer et al., 1994; Young
et al., 1994, 1995, 1997; Fisher and Coderre, 1996a,b; Fundytus et
al., 1998). Specifically, our pharmacological and antisense abla-
tion data suggest strongly that a key role is played by mGluR1.
This is consistent with our previous evidence from partially
selective pharmacological agents that suggested that mGluR1 may
play the predominant role (Young et al., 1995, 1997). Both the
acute responses to mustard oil (a C-fiber selective activator) and
the incremental activity resulting from its repeated application
were severely inhibited by mGluR1 ablation (Fig. 2; Table 2), with
relative preservation of responses to innocuous brush. It is not
possible from the present results to say whether mGluR1 ablation
has any specific influence on the mechanism of wind-up (in-
creased excitability) per se, because the necessary prerequisite of
C-fiber inputs is itself abrogated by the antisense strategy. The
behavioral studies (Fig. 1) and previous reports with partially
selective mGluR1 antagonists and mGluR1/mGluR5 antisera
(Young et al., 1997; Fisher and Coderre, 1996a; Fundytus et al.,
1998) are entirely consistent with these observations in showing
that prevention of spinal mGluR1 function leads to inhibition of
behavioral nociceptive responses.
However, mGluR1 sites are also present in ventral horn, on or
around motoneurons (Anneser et al., 1995; Alvarez et al., 1997;
Boxall et al., 1998) . Thus, effects of mGluR agents on ventral root
potentials evoked by dorsal root stimulation (Boxall et al., 1996)
are likely to represent a composite of actions in dorsal and ventral
horn. Group I mGluR agonists increase ventral root potentials
elicited by ionotropic GluR agonists (Ugolini et al., 1997),
whereas intracellular recordings from motoneurons suggest that
both postsynaptic facilitatory and presynaptic inhibitory effects
are brought about by group I/II mGluR agonists (King and Liu,
1996). Presynaptic effects of group III mGluR agonists are also
Table 3. Image analysis quantification of immunohistochemistry for mGluR1 and mGluR5 in dorsal horn
of animals treated with mGluR1 oligonucleotides
Gray scale intensity (arbitrary units) in excess of dorsal column control
Control mGluR1 sense mGluR1 mismatch mGluR1 antisense
mGluR1
Lamina I 96.5 6 1.1 95.4 6 2.0 94.8 6 1.5 86.8 6 2.9
Lamina II0 98.6 6 0.6 97.2 6 1.6 95.3 6 1.3 84.5 6 3.4*,***,****
Lamina III 80.3 6 2.7 70.5 6 5.0 75.0 6 1.7 53.1 6 3.3**,***,*****
Lamina III 23.3 6 3.0 20.3 6 2.2 25.9 6 2.2 16.5 6 4.8
Ventral horn 26.3 6 2.0 22.7 6 1.8 28.0 6 6.3 25.7 6 1.0
mGluR5
Lamina I 70.6 6 2.8 82.3 6 2.5 77.2 6 2.5 80.4 6 2.8
Lamina II0 66.7 6 2.8 73.5 6 2.9 58.3 6 3.8 71.8 6 4.5
Lamina III 43.3 6 3.3 47.4 6 3.0 36.9 6 2.8 43.9 6 3.7
Lamina III 17.9 6 2.5 13.7 6 2.3 17.4 6 3.0 13.8 6 2.4
Ventral horn 32.0 6 1.3 28.5 6 2.3 26.7 6 2.7 30.4 6 2.0
The statistically significant differences were determined by Mann–Whitney U test (n 5 15–16). *p , 0.05, **p , 0.01
compared with control; ***p , 0.05 compared with sense; and ****p , 0.05, *****p , 0.01 compared with mismatch.
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prominent in motoneuron recordings (Cao et al., 1997). It is
clear, therefore, that ventral horn effects of mGluR agents may
potentially contribute to, or at least modify, the effects of mGluR
manipulations in behavioral analgesia experiments. However, in-
creased latencies or thresholds to nociceptive stimuli were mea-
sured in behavioral responses to intrathecally applied mGluR
group I antagonists in the absence of any overt signs of motor
insufficiency (Fisher and Coderre, 1996a; Young et al., 1997).
Similarly, although mGluR1 knock-out mice display a disruption
of complex coordination behaviors that may arise from cerebellar
dysfunction, they possess well maintained muscle strength and
can organize effective goal-oriented swimming behaviors as well
as normal animals (Conquet et al., 1994). In the present study,
there was no evidence for any deficit in motor coordination, gait,
or locomotor activity in the mGluR1 intrathecal antisense-treated
animals, corresponding to the lack of change in ventral horn
mGluR1 immunoreactivity (Fig. 3F,G) after dorsally directed
infusion of oligonucleotide. So, although it is not possible to
unequivocally exclude a contribution of ventral horn effects to the
behavioral results (and reflex indices of function here not tested),
it is clear that the effects of mGluR1 ablation (focused in the
dorsal horn; Fig. 3, Table 3), as defined in the electrophysiological
experiments (Table 2, Fig. 2), would alone be quite sufficient to
explain the behavioral changes that we observed (Fig. 1) and have
similarly been described in mGluR1 knock-out mice (Corsi et al.,
1996).
In conclusion, the present results demonstrate that the local-
ized antisense ablation of mGluR1 in dorsal horn (without affect-
ing the congener mGluR5) results in a selective abrogation of
neuronal responses to noxious stimuli (and perhaps also sensiti-
zation) without equivalent changes in non-nociceptive responses.
Correspondingly, reflex behavioral responses to noxious thermal
stimuli are attenuated in rats with antisense deletion of mGluR1
in lumbar dorsal horn, in the absence of any signs of generalized
motor deficit.
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